

DEEP
KNOWLEDGE
GROUP



Longevity
Industry
Analytics

Global Autism and ASD Overview

January, 2024

Table of Contents

Introduction	2
Executive Summary	3
Epidemiological Data	5
Clinical Trials for Autism Spectrum Disorder	10
Global Impact and Celebrities Involvement	18
Global Autism Spectrum Disorder Market Analysis	22
Global ASD Diagnostics and Treatment	26
Impact on Public Health	31
Conclusions	35
Disclaimer	40

Introduction

The recently unveiled report titled “Global Autism Disease Overview 2023” by Longevity Industry Analytics and Deep Knowledge Group extensively examines the complex landscape of Autism disease, offering insights into its worldwide implications and the intricate workings of the industry.

Exploring the far-reaching impact of Autism as a prevalent health issue, the report delves into its relationship with other conditions like Alzheimer's and Lyme Disease, presenting the latest scientific findings, epidemiological data, and their implications for public health. Additionally, it provides an overview of the Autism industry, including key stakeholders, collaborative efforts, and emerging market trends.


The report delves into the challenges and opportunities in Autism diagnosis and treatment, and anticipates future regulatory considerations. Moreover, it addresses the involvement of celebrities, parliamentary initiatives, and the vital need for collaborative endeavors, all crucial aspects of this extensive exploration.

Executive Summary

Autism is a multifaceted neurodevelopmental condition characterized by challenges in social communication and interaction, alongside restricted and repetitive behaviors. Its prevalence stems from various factors, including genetic susceptibilities and environmental influences. Changes in societal behaviors, environmental shifts, and lifestyle alterations have significantly impacted Autism's occurrence globally.

The estimated prevalence of Autism spectrum disorder is around **1 in 54 children globally**, according to the Centers for Disease Control and Prevention (CDC). This statistic may vary based on different studies and regions. Understanding the intricate factors influencing Autism's prevalence is crucial in formulating effective strategies for prevention, diagnosis, and management. One notable hypothesis links a substantial part of the increase in Autism prevalence to the **ongoing global Lyme Disease Pandemic**.

Prevalence of Autism Disease



Link Between Lyme, Autism and Alzheimer

Understanding Age-Specific and Groups Impact

Adults

Neurological Implications, Inflammatory Response

Kids

Maternal Transmission, Inflammatory Impact

Seniors

Age-Related Vulnerabilities, Inflammatory Response

Animals

Neurological Concerns, Inflammatory Response


Lyme is a chronic health condition that manifests unique neurological implications across age groups, with notable associations to **Autism in children** and **Alzheimer's in seniors**. Scientific endeavors aim to unravel the molecular pathways connecting Lyme disease to the development of Autism in children and Alzheimer's in seniors. Research delves into the complexities of how Lyme-induced factors may influence neurodevelopment in children and contribute to neurodegeneration in seniors.

Case studies provide insights into the intricacies of the link, offering valuable **perspectives on diagnosis, prevention, and potential interventions**. As we navigate through this report, we will explore the age-specific nuances of the link between Lyme disease and neurological conditions, shedding light on the complexities and implications for different age groups.

Epidemiological Data


Significance of Autism Disease as a Global Health Challenge

Number of articles on Autism Disease, 2000-2023, Pubmed database



Estimates suggest that **Autism Spectrum Disorder (ASD)** affects **more than 1% of the global population**. This growing prevalence is reflected not only in its substantial impact on millions of individuals worldwide but also in the escalation of related PubMed articles over the years, signaling increased research attention. ASD's complex presentations strain healthcare systems globally, emphasizing the urgency for heightened awareness and targeted interventions. Connections between ASD and conditions like **Lyme** and **Alzheimer's disease** further intensify the challenge, demanding collaborative efforts for effective prevention and management strategies.

Longevity Industry and Autism Disease




Structure of the Autism Market by Company Type

Autism is a complex neurodevelopmental condition that affects social interaction, communication abilities, and behavior patterns. Its prevalence has been steadily increasing, with current estimates suggesting that about **1 in 54 children** is diagnosed with Autism spectrum disorder in the United States. Autism has seen a rise in public awareness and recognition over the past few decades. Contributing factors to Autism prevalence include both genetic susceptibilities and environmental influences, warranting extensive research into its etiology.

As part of the healthcare landscape, the **Autism market** encompasses diverse sectors, such as therapeutic interventions, diagnostic technologies, and technological advancements tailored to enhance patient care and support. With a growing emphasis on technological innovations, healthcare providers and stakeholders are working towards improving diagnostic tools and treatment approaches to better meet the needs of individuals affected by Autism spectrum disorder.

Structure of the Autism Market



Key Global Findings



By 2023, the global population has surpassed 8.14 billion. It's estimated that between 1-2% of this populace—over 75 million individuals—are affected by Autism Spectrum Disorder, with figures varying based on precise clinical definitions. The economic impact in the US alone is substantial, surpassing US\$400 billion due to ASD-related medical, nonmedical, and productivity losses.

Clinical Trials for Autism

Autism Clinical Trials, 1996-2023

502

*Ongoing Autism and ASD
clinical trials in the world*

1646

Clinical trials for Autism and ASD

167

Clinical trials started in 2023

146

*Clinical trials are sponsored
by Industry*

876


Clinical trials in United States

26

Ongoing clinical trials in Phases 3-4

Geography of Clinical Trials, 2023

Countries by Number of Clinical Trials for Autism Spectrum Disorder



1646 clinical trials were conducted on Autism Spectrum Disorder in the world.


US is the biggest research hub for ASD research, containing more than **53%** of clinical trials.

More than **5%** of clinical trials are launched in **France**. **Canada**, **Taiwan**, **UK** and **China** have similar number of clinical trials, each around **3%**. Together, European countries make more than **18%** of clinical trials.

In total, **more than 50 countries** have participated in Autism Spectrum Disorder clinical trials.

ASD Clinical Trials by Status

ASD Clinical Trials by Status




ClinicalTrials.gov listed **1646** trials for Autism Spectrum Disorder. For analysis we include **502** active (“recruiting”, “not yet recruiting”, “enrolling by invitation”, “active, not recruiting”) and **1144** not active (“suspended”, “terminated”, “completed”, “withdrawn”, “unknown status”) trials. The **average number** of clinical trials is **60 studies per year**.

After 2017, the annual number of clinical trials **increased to 134 studies per year**. The consistent increase in the number of clinical trials indicates a growing acknowledgment of the significance of Autism Spectrum Disorder.

Top Sponsors Providing Clinical Trials, 2023

Companies by Number of Clinical Trials




ASD research is an established and popular area for clinical research. The most significant players in the market are **Massachusetts General Hospital** (USA), **Stanford University** (USA), **National Taiwan University Hospital** (Taiwan), **Yale University** (USA), **University of California, Los Angeles** (USA), **Children's Hospital Medical Center, Cincinnati** (USA), **National Institute of Mental Health** (USA).

Six companies have been sponsors for 15-19 clinical trials on ASD: **Emory University** (USA), **University of North Carolina, Chapel Hill** (USA), **Boston Children's Hospital** (USA), **Hugo W. Moser Research Institute at Kennedy Krieger, Inc.** (USA), **Assistance Publique - Hôpitaux de Paris** (France), **University of California, San Francisco** (USA).

Most leading sponsors are thus from USA, but some significant sponsors are from Taiwan and France.

Clinical Trials Structure by Type of Investigation


Proportion of Clinical Trials by Approach




Around **39.1%** of clinical trials are dedicated to exploring behavioral interventions. Drug interventions and exploring new devices make up about **24.6%** and **8.2%** of the trials respectively. The remaining **28.1%** encompasses a broad spectrum of other investigative fields, including diagnostic tests and genetic interventions.

Structure of Clinical Trials, 2023

Proportion of Clinical Trials by Enrollment, 1997-2023



Proportion of Clinical Trials by Status



As of 2023, more than **51%** of clinical trials between 1997 and 2023 are completed (**853** trials), about **30%** are active (**502** trials), and around **7%** are terminated, withdrawn or suspended (**111** trials).

About **29%** of clinical trials enrolled more than 100 participants, and **5%** enrolled more than 500 participants.

Case Study: AI for Autism Disease Diagnostics



Researchers at the **University of South Australia** and **Flinders University** have devised an innovative AI-powered method to diagnose autism spectrum disorder (ASD) swiftly and non-invasively. Using **electroretinogram (ERG)** responses to a flash of light in children aged 5-16, the study identified distinct retinal differences between those with ASD and neurotypical individuals. This promising test could significantly expedite ASD diagnoses, offering quicker interventions and support for affected children.




Stanford researchers have developed an AI-based algorithm using **fMRI scans** to accurately identify autism spectrum disorder in patients with an **82% success rate**. By analyzing unique brain activity patterns, the algorithm shows promise in predicting autism severity and could lead to earlier diagnoses, targeted therapies, and a better understanding of the disorder. Additionally, the algorithm's **explainable AI (XAI)** model revealed specific brain regions associated with autism, offering potential for early detection in high-risk infants, which may improve intervention outcomes.



Duke University's AI-driven app, SenseToKnow, uses a tablet to screen for autism by analyzing behavioral indicators. This interpretable tool aids healthcare providers by providing detailed insights into a child's potential autism diagnosis, eliminating disparities in early identification across diverse demographics. SenseToKnow's accuracy, especially when combined with standard questionnaires, improves the chances of identifying children on the autism spectrum, potentially filling gaps in early detection.

Global Impact and Celebrities Involvement

Billionaires families affected by Autism disease



> 100

*Billionaires
have close relatives
with ASD*

Over **100** billionaires have close relatives with ASD. This significant figure underscores the widespread impact of the disease across various demographics, highlighting the need for continued awareness, research, and support for those affected in high-profile spheres.

Notable Celebrities in Autism Spectrum Disorder Support Initiatives

Portia Iverson



Co-founder of Cure Autism Now (CAN), Portia Iverson's organization funded autism research and advocated for families affected by autism. Her contributions significantly advanced understanding and support initiatives for individuals with ASD.

Holly Robinson Peete



A well-known actress, Holly Robinson Peete co-founded the HollyRod Foundation. This organization is committed to supporting families affected by ASD and Parkinson's disease, reflecting her passion for providing resources and a supportive community.

Ari Ne'eman



Co-founder of the Autistic Self Advocacy Network (ASAN), Ari Ne'eman is a dedicated advocate for the rights and inclusion of individuals with autism. His advocacy work emphasizes self-advocacy and autonomy for individuals on the spectrum.

Steve Silberman



Renowned for his book "NeuroTribes: The Legacy of Autism and the Future of Neurodiversity," Steve Silberman explores the societal perceptions and history of autism. His insightful work sparks crucial discussions on neurodiversity and acceptance.

Alex Plank



As the founder of the Wrong Planet website, Alex Plank created a vital online community for individuals on the autism spectrum. This platform serves as a valuable resource hub, offering support, information, and a sense of belonging for individuals with ASD.

Chantal Sicile-Kira



An author and advocate specializing in autism and adolescence, Chantal Sicile-Kira provides crucial resources and support for individuals transitioning into adulthood. Her guidance empowers individuals with ASD and aids their successful transition into adulthood.

Involvement of Celebrities in ASD Awareness



Dan Aykroyd



Jim Parsons



Sylvester Stallone



**Holly Robinson
Peete**



Daryl Hannah



Colin Farrell



**Matthew
McConaughey**



**Benedict
Cumberbatch**



Toni Braxton



Jenny McCarthy



Halle Berry



Zack Snyder



**Julia
Louis-Dreyfus**



**Morgan
Freeman**



Michael Phelps



David Beckham



Amanda Seyfried



Chris Packham



**Evan Rachel
Wood**



Jerry Seinfeld



Will Ferrell



**Sarah Jessica
Parker**



Joe Mantegna




Alicia Keys


Global Autism Disease Market Analysis

Market at a Glance: Autism Clinics

Distribution of Clinics by Country, %




Distribution of top 300 ASD Clinics by Type, %



The Global Autism Disease Diagnostic, Treatment, and Prevention Market is segmented here based on countries and categories.

The **majority** of the best clinics that offer services against ASD are located in the **USA** and the **UK**, the home of **30%** and **21%** of the whole range of companies analysed in the report. The USA is distantly followed by the China with **12%**, Canada with **10%**, and other countries, which together host remaining **20%** of the world's best ASD clinics.

Application of Innovative Approaches for ASD Management



Autism Industry Framework

Treatment

Autism Treatment

Gene and Cell Therapy

Small Molecules

Drug Delivery Systems

Supplements

Formulations (drugs)

Probiotics

Natural Products

Clinics

Autism Screening
and Management

Clinical Trials
Management

Nursing

Rehabilitation

Patient Monitoring
and Management

EHR

Residential, Home and
Elder Care

Assisted living

MedTech

Medical Supplies and
Equipment, Raw
Material

Devices (diagnostics,
therapy)

Medical Suppliers

Diagnostics, Tests and
Labs

E-Pharmacy

Medical Devices
(Artificial Organs)

Imaging

Organ Engineering

Biologics (RNA,
vaccines, AB)

Genomics and
Genetics

AI for Drug Discovery

CRO

AI for Diagnostics
(Omics, Imaging)

Physiological,
Systemic and Digital
Biomarkers

Scientific innovation

Insurance

Contract
Manufacturing

Clinical Data Storage
and Management

Education platforms

Media

Non-Profits

Civil services

Early Screening

Healthy Lifestyle

Genetic Testing

Support Services

Timely Treatment of
Lyme Disease

Community Inclusion


Prevention and Care

Global ASD Diagnostic and Treatments


Autism Diagnostic Methods

Diagnostics for autism comprise various pivotal methods crucial for precise identification. Behavioral assessments involve observing and analyzing an individual's social interaction, communication patterns, and behavior, aiding in early detection but might not capture subtler signs in some cases. Psychological evaluations aim to assess cognitive functions and developmental milestones, providing valuable insights into a person's strengths and challenges. Genetic tests explore specific genetic markers associated with autism, offering more targeted insights. Additionally, brain imaging techniques, such as functional MRI, provide a window into brain activity and connectivity, enhancing our understanding of autism neurological underpinnings.

Autism Spectrum Disorder (ASD) embodies a continuum that captures a wide array of behaviors and characteristics. At one end, individuals may exhibit slight variations that fall within the range of typical behavior. Moving through the spectrum, there's a diversity of presentations, encompassing varying degrees of challenges in communication, social interaction, and sensory processing. Towards the other end, ASD manifests more prominently, with more pronounced difficulties that significantly impact daily functioning.



ASD Diagnostic Market Size



The Compound Annual Growth Rate (CAGR) for this period is **~8%**. This expansion is fueled by several factors, including heightened awareness and reporting of Autism Spectrum Disorder (ASD) cases, advancements in diagnostic technologies, and ongoing investment in research and development aimed at creating more precise and effective diagnostic tools for detecting ASD.

The market is projected to expand steadily **from USD 2 Billion in 2022 to USD 5.4 Billion in 2032**, highlighting the rising need for advanced diagnostic tools to detect Autism Spectrum Disorder, aiming for earlier identification and improved condition management.

Advanced Treatments for Autism Disease

Hyperbaric Chamber



Presently, the predominant approach in managing **Autism Spectrum Disorder (ASD)** involves behavioral therapies and early interventions, highly effective in the initial developmental stages of the condition. Alongside these interventions, **intermittent hypoxic-hyperoxic treatment** and hyperbaric chambers are emerging as potential adjunct therapies. These treatments, known for their benefits in chronic diseases and aging, exhibit promise in enhancing immunity and improving overall health.


Brain Imaging



Intensive interventions like **applied behavior analysis** or speech-language therapy may become necessary. Individuals who experience persistent challenges post-treatment, termed post-treatment ASD syndrome, might need customized therapies or additional support. To address specific symptoms or behavioral issues, certain cases may benefit from medication, such as mood stabilizers or antipsychotics.

ASD management promotes an expansive range of interventions, integrating alternative therapies like sensory integration therapy, music/art therapy, animal-assisted therapy, and dietary adjustments. Embracing a holistic approach, ASD care acknowledges the intricate connections between mental, emotional, and physical well-being, recognizing the nuanced nature of treatment.

Autism Spectrum Disorder Treatment Market Size



The global Autism Spectrum Disorder treatment market is expected to witness substantial growth, climbing from **USD 29.8 Billion in 2021** to **USD 45.9 Billion in 2032**, representing a robust Compound Annual Growth Rate (CAGR) of approximately **4.4%**.

Advancements in healthcare, fueled by increased investments from major corporations and government institutions, highlight the growing importance of refined treatment approaches and accurate diagnostics in addressing the complexities of Autism Spectrum Disorder (ASD), including aiding individuals with mild forms, ensuring comprehensive support for the spectrum's entire range.

Impact on Public Health

Impact on Public Health

The prevalence of autism spectrum disorder (ASD) has a profound impact on public health, demanding comprehensive strategies to address its effects. Understanding and meeting the needs of those with ASD contributes to overall public health initiatives.

Increased Disease Burden

Increasing autism rates pose a growing challenge to public health initiatives, amplifying the disease burden. Applying modern and prospective AI and data driven diagnostic and treatment methods are crucial in confronting this challenge.

Diagnostic Challenges

The diagnostic complexities of autism present considerable challenges in public health strategies. The spectrum nature of autism introduces diverse and multifaceted challenges, further complicating public health strategies aimed at diagnosis and intervention within this realm.

Treatment Accessibility

Ensuring accessible and equitable treatment avenues for individuals with autism is a pivotal aspect. Geographical gaps in treatment accessibility for autism lead to unequal care. Addressing these disparities requires outreach programs and telehealth initiatives.

Strain on Healthcare Systems

The growing prevalence of Autism and ASD creates strain on healthcare systems, necessitating increased resources, and extended care provisions. These conditions also lead to large indirect costs, emphasizing the need for improved support and infrastructure within healthcare systems.

Public Awareness

Promoting public awareness about modern treatments for Autism and ASD is crucial, fostering understanding and support for affected individuals and their families. Educating communities about these innovative approaches can help improve quality of life for millions of people with ASD.

Collaborative Surveillance

Collaborative surveillance in Autism and ASD involves multidisciplinary efforts to collect and analyze data, fostering a shared understanding of the disorder prevalence and patterns. This collaborative approach aids in refining diagnostic criteria and intervention strategies across various healthcare settings.

Special Parliament Groups



Congressional Coalition for Autism Research and Education (C.A.R.E.)

The Congressional Coalition for Autism Research and Education (C.A.R.E.) is a bipartisan force within the U.S. Congress, leading legislative efforts, championing policies, and diligently partnering to enhance research funding through federal agencies like the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC). Committed to fortifying support networks, this alliance plays a pivotal role in raising awareness and advancing essential initiatives for individuals and families navigating the intricate journey of autism spectrum disorder (ASD) across the nation. Through collaborative endeavors, it aims to shape a more inclusive and supportive environment for the ASD community.



All Party Parliamentary Group on Autism (APPGA)

In the United Kingdom, the All Party Parliamentary Group on Autism (APPGA) stands as a crucial forum within Parliament, advocating for the needs of individuals with autism spectrum disorder (ASD) and their families.

Comprising Members of Parliament (MPs) and peers from various political backgrounds, the APPGA plays a central role in shaping policies, conducting inquiries, and spearheading awareness campaigns focused on ASD-related challenges. Through collaborative efforts, it seeks to influence legislation and promote initiatives across key sectors such as education, healthcare, employment, and social services, aiming to enhance the quality of life for those affected by ASD throughout the UK.

Key Takeaways for Government Initiatives and Special Parliament Group



Government Commitment to Autism Disease: Numerous countries, including the US, Canada, UK, Germany, among others, have instituted governmental bodies and healthcare agencies specifically focused on Autism Spectrum Disorder (ASD) awareness, prevention, research, and surveillance. These establishments offer information, guidelines, and resources aimed at tackling the intricacies of Autism Spectrum Disorder.



International Research Initiatives: Institutes and hospitals like the Massachusetts General Hospital in the US, the Chinese University of Hong Kong in China, Assistance Publique–Hôpitaux de Paris in France and similar organizations in Canada, Taiwan, UK, and other countries are actively involved in conducting research and surveillance for ASD.



Global Collaboration and Surveillance: Collaboration across nations is apparent in the endeavors of several health agencies, exemplified by NIH extramural grants, the International Collaboration for Diagnostic Evaluation of Autism (IDEA), and numerous other initiatives. These agencies actively participate in monitoring, prevention, and management of conditions related to ASD, underscoring a global commitment to address these healthcare complexities.



Legislative Advocacy and Awareness: Special parliamentary groups, such as the United States Congressional Autism Caucus and the All-Party Parliamentary Group on Autism in the UK, showcase legislative initiatives aimed at addressing concerns related to Autism Spectrum Disorder (ASD). These groups actively strive to increase awareness, facilitate discussions, and advocate for enhanced support and resources for individuals impacted by ASD within their nations.

Conclusions

Conclusions

- The Autism Spectrum Disorder poses complex challenges for public health, demanding proactive measures. Collaborative efforts from healthcare professionals, policymakers, and the community are essential. By boosting awareness, advancing research, more actively using advanced treatment methods like intermittent hypoxic-hyperoxic treatment, we can address the impact of Autism Spectrum Disorder rising prevalence on global health. Exploring the possible link between increasing Lyme disease prevalence and growing ASD incidence requires comprehensive research and heightened awareness.
- In the realm of ASD, we witness complexities and challenges mirroring the dynamic healthcare landscape. Unlike certain markets dominated by well-defined monopolies, Autism Spectrum Disorder involves a diverse array of stakeholders, encompassing pharmaceutical companies, diagnostic innovators, and treatment specialists.
- As we navigate the complexities of Autism Spectrum Disorder, exploring its potential links to persistent inflammation, compromised immune function, and potential associations with age-related conditions, the emphasis remains on promoting innovation and research. Unlike certain sectors marked by concentrated control, the Autism landscape encourages a diverse array of contributors in diagnostics, treatments, and preventive approaches..
- While the Autism market may not have dominant giants as seen in some industries, the combined endeavors of diverse contributors—pharmaceutical firms, researchers, and healthcare providers—serve as the propelling force.

Conclusions

- The majority of companies offering diagnostic and healthcare services are **in the USA (30%) and in the UK (21%)**. The main types of the clinics that offer the services are **Precision Medicine** and **Neurohacking**, which account for **54.7%** and **16.7%** of all companies **respectively**.
- **53%** of **1646** clinical trials on ASD comes from United States, but **more than 50 countries** have participated in Autism Spectrum Disorder clinical trials. The **average number** of clinical trials is **60 studies per year**. After 2017, the annual number of clinical trials **increased to 134 studies per year**.
- Present **ASD** management focuses on symptom-based diagnosis, antibiotics, and supportive care. Future strategies aim for early advanced diagnostics through AI based algorithms, potentially including **early predictive genetic screening** at the prevention stage. Advanced treatments like **hyperbaric therapy**, **intermittent hypoxic-hyperoxic treatment**, **brain stimulation and neurofeedback techniques** show promise.
- ASD diagnostics shows a consistent **8%** annual growth due to increased awareness, better reporting, and improved diagnostic technologies. The market is forecasted to grow from **USD 2 Billion** in **2023** to **USD 5.4 Billion** by **2036**, signaling a growing demand for advanced tools. These innovations promise earlier detection and enhanced management of Autism Spectrum Disorder.
- The global ASD treatment market is set to grow significantly from **USD 29.8 Billion** in **2021** to **USD 45.9 Billion** by **2032**. This expansion is propelled by increased reported cases, higher healthcare investments, advanced facilities, and more accurate diagnostic methods like Raman spectroscopy testing. These factors are spurring a greater demand for enhanced Autism Spectrum Disorder treatment and diagnostics.

Conclusions

- Governments globally acknowledge the importance of **Autism Spectrum Disorder** (ASD) direct and indirect costs both in life quality and in billions of US dollars, and have taken proactive steps to tackle its challenges. **Over 50 countries** have formed parliamentary groups and governmental initiatives, uniting efforts to boost awareness, research, and policies. This collaborative approach aims for a holistic response to the ASD.
- Legislative groups like the **Congressional Coalition for Autism Research and Education (C.A.R.E.)** in the United States and the **All Party Parliamentary Group on Autism (APPGA)** in the UK bring together legislators to amplify awareness, promote deeper understanding, and champion the cause of those impacted. Their goal is to foster collaboration, enact policies, bolster resources, and fortify support systems for individuals affected by **ASD**.
- Research suggests a potential correlation between **Lyme disease** and the prevalence of **Autism Spectrum Disorder**, indicating a plausible link in understanding ASD's etiology. **Intermittent hypoxic-hyperoxic treatment**, in conjunction with **hyperbaric chambers**, emerges as a promising avenue to alleviate ASD symptoms. These therapies not only show promise in addressing ASD but also **exhibit positive effects on immunity and aging** processes, offering a multifaceted approach toward enhancing overall well-being.
- ASD touches the lives of **over 100 billionaire families**, underscoring its far-reaching impact across various demographics. This highlights the ongoing interest for research for modern high-efficiency treatments and diagnostics for affected individuals, including within influential circles.

Longevity Industry Analytics: Value Proposition

Visit Website



Longevity Industry Analytics is the only specialised analytics agency that focuses exclusively on the emerging Longevity Industry. We are recognised internationally as the premier analytics agency for advanced data analysis, industry reports, and next-generation infographics on ageing and Longevity.

Longevity Industry Analytics focuses on three key activities:

Providing Commercial Services




Conducting customised case studies, research, and analytics for internal (organisational) use, tailored to the precise needs of specific clients.

Preparing Open-Access Reports

Producing regular open-access and proprietary analytical case studies on the emerging topics and trends in the Longevity Industry.

Building Big Data Analytics Platforms

Offering customised analysis using specialised interactive industry and technology databases, IT-platforms, and Big Data Analytics Dashboards.



Website: www.aginganalytics.com



E-mail: info@aginganalytics.com

Website: www.aginganalytics.com

Longevity Industry Analytics (LIA) Disclaimer.

The information and opinions in this report were prepared by Longevity Industry Analytics. The information herein is believed by LIA to be reliable but LIA makes no representation as to the accuracy or completeness of such information. There is no guarantee that the views and opinions expressed in this communication will come to pass. LIA may provide, may have provided, or may seek to provide advisory services to one or more companies mentioned herein. In addition, employees of LIA may have purchased or may purchase securities in one or more companies mentioned in this report. Opinions, estimates, and analyses in this report constitute the current judgment of the author as of the date of this report. They do not necessarily reflect the opinions of LIA and are subject to change without notice. LIA has no obligation to update, modify, or amend this report or to otherwise notify a reader thereof in the event that any matter stated herein, or any opinion, estimate, forecast, or analysis set forth herein, changes or subsequently becomes inaccurate. This report is provided for informational purposes only. It is not to be construed as an offer to buy or sell or a solicitation of an offer to buy or sell any financial instruments or to participate in any particular trading strategy in any jurisdiction.